OptimizeRx Corporation OPRX 深 滬
等待開盤 06-26 09:30:00 美东时间
4.90
+0.160
+3.38%
華盛通- 最 高5.01
- 今 開4.80
- 成交量 61.32万股
- 最 低 4.7503
- 昨 收 4.74
- 總市值 9194.89万
- 52周最高 22.25
- 市盈率 靜 18.14
- 換手率 3.27%
- 52周最低 4.54
- 委 比 73.91%
- 總股本 1876.51万
- 歷史最高 99.178
- 量 比 1.07
- 振 幅 5.48%
- 歷史最低 3.78
- 每 手 1
- 風險率 4.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OptimizeRx Shareholders Expand Equity Plan, Maintain Oversight
OptimizeRx ( ($OPRX) ) has shared an announcement. At its June 9, 2026 annual m...
06-13 04:43
OptimizeRx's Electronic Health Record Network Integrated By DeepIntent
OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important decision points, today
05-21 19:31
OptimizeRx partners with DeepIntent to integrate authenticated EHR network into DSP platform
OptimizeRx partners with DeepIntent to integrate authenticated EHR network into DSP platform OptimizeRx entered a partnership with healthcare advertising platform DeepIntent to integrate its authenticated electronic health record network into DeepIntent’s demand-side platform. The tie-up gives life
05-21 19:31
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $17 to $14.
05-13 21:45
美股异动丨OptimizeRx盘前跌4% Q1营收降10%但盈利翻倍 下调全年指引
格隆汇5月13日｜专注于医疗健康领域的数字技术公司OptimizeRx(OPRX.US)盘前跌4%报6美元。消息上，OptimizeRx于5月12日盘后公布了...
05-13 17:16
OptimizeRx Reports Q1 2026 Results: Full Earnings Call Transcript
OptimizeRx (NASDAQ:OPRX) released first-quarter financial results and hosted an...
05-13 05:08
OptimizeRx Secures New Credit Facility to Boost Flexibility
OptimizeRx ( ($OPRX) ) just unveiled an announcement. On May 7, 2026, OptimizeR...
05-13 05:01
OptimizeRx Lowers FY2026 Sales Guidance from $109.000M-$114.000M to $95.000M-$100.000M vs $111.438M Est
OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $109.000 million-$114.000 million to $95.000 million-$100.000 million vs $111.438 million estimate.
05-13 04:12
OptimizeRx Q1 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $19.844M Beat $18.353M Estimate
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 75 percent increase over earnings of $0.08 per share from the same
05-13 04:12
